Author name: admin

SINGAPORE – Media OutReach Newswire – 31 July 2025 – Oriental Remedies Clinic, a Traditional Chinese Medicine (TCM) clinic chain in Singapore, has announced the opening of its new clinic in Punggol. Located at Punggol Coast Mall, the chain’s fifth branch aims to cultivate a sanctuary for holistic family wellness, prioritising a nurturing and stress-free environment that offers a child-friendly experience for all ages. Warm, personalised TCM care for the whole family at Oriental Remedies Clinic, delivered in a thoughtfully designed space. New Clinic Opening for Families in Punggol Coast Mall The new TCM clinic is designed as a welcoming space where families can experience the TCM principle of Yang Sheng, the art of life cultivation. More than just a treatment centre, it encourages individuals and children to build lifelong habits that promote balance, vitality, and preventive care. Developed in collaboration with House on the Hill, a renowned Montessori preschool in Singapore, the clinic features a sensory-focused waiting area thoughtfully designed to engage children through their five senses, transforming passive waiting into active discovery. Children are invited to explore traditional Chinese herbs, textures, scents, and natural materials in a calm, tactile environment. This immersive setup encourages curiosity, independent participation, and self-directed play, reflecting our core belief in nurturing lifelong wellness from an early age. Every aspect of the clinic promotes emotional comfort and a restorative atmosphere. A natural colour palette of muted greys and warm earth tones, complemented by carefully curated toys suited to different developmental stages, helps children feel grounded and focused. This intentional design supports emotional regulation and encourages internal awareness, an essential foundation for the mind-body connection central to TCM healing practices. Enhancing Comfort with Child-Friendly Design The clinic features an open-concept layout, where the paediatric pods for consultations and treatments are designed as a natural extension of the children’s play area, offering a seamless transition from exploration to treatment. This thoughtful continuity reduces anxiety by preserving a sense of familiarity and playfulness, helping consultations feel more conversational and less clinical. These pods are intentionally designed to encourage gentle interaction, open communication and engagement, helping children stay emotionally regulated and present. This approach keeps children engaged and interested in their bodies and feelings, fostering a sense of ownership in their wellness journey. The open-concept design facilitates parental supervision, allowing the clinic to foster guided independence in children. Through this approach, the clinic helps empower children to understand and make choices that support their well-being. This transparency is key to the collaborative, family-centred approach at Oriental Remedies Clinic. Expanding Core Services to Support Paediatric Care In addition to Oriental Remedies Clinic’s comprehensive suite of treatments, including acupuncture, herbal medication, paediatric tuina, and tech-enhanced therapies such as Electro-Lymphatic Therapy (ELT), the new branch will introduce more child-focused therapies, such as paediatric moxibustion, herbal vaporiser therapy, and Cell Pro Therapy for children. These specialised additions reflect the clinic’s dedication to delivering tailored, gentle, and effective care while actively encouraging children’s participation in their health education from an early age. The Punggol outlet will also serve as an educational platform through intimate community workshops. Covering practical topics such as “Understanding Big Emotions through TCM,” “Supporting Your Child’s Immune System Naturally,” and “Healthy Foods for Your Body Constitution,” these workshops aim to reinforce the critical link between emotional resilience, physical health, and lifelong wellness. Integrating Tradition with Technology in Punggol’s Digital District Located at Punggol Coast Mall within the Punggol Digital District (PDD), the clinic’s opening aligns with Singapore’s push for innovation in healthcare. Oriental Remedies Clinic is actively exploring ways TCM can evolve through advancements in artificial intelligence, data analytics, and smart diagnostics. Current initiatives include research into AI-assisted tongue and pulse diagnosis, and personalised treatment plans informed by data analytics. These advanced technologies aim to enhance the precision of care without compromising the personalised, hands-on essence of traditional TCM practice. In the long term, the clinic hopes to collaborate with research institutions and tech firms within PDD to further integrate cutting-edge innovations into TCM. This forward-looking approach supports Oriental Remedies Clinic’s vision of becoming a modern, future-ready wellness provider—empowering practitioners with technology to deliver more precise, effective, and accessible care. Supporting Healthier SG Through Early Education The expansion into Punggol reflects Oriental Remedies Clinic’s dedication to Singapore’s Healthier SG initiative, which prioritises preventive care. Understanding that establishing strong health foundations begins in childhood, the new clinic aims to help introduce TCM principles and healthy lifestyle practices in an engaging manner. By creating child-friendly spaces that foster curiosity and proactive exploration of natural remedies, the clinic chain helps children and families build strong foundations for lifelong health. This approach cultivates balanced living from an early age, ultimately reducing the incidence of chronic illnesses later in life. Through empowering children to embrace healthy habits from a young age, the chain looks to actively contribute to a more resilient and healthier Singapore. Serving the Punggol Community Through Holistic Care According to Beatrice Liu, CEO and co-founder of Oriental Remedies Clinic, the decision to open a new branch in Punggol was driven by the area’s growing population and its high concentration of young families.“Punggol represents a vibrant, forward-looking community, and we see an immense opportunity to partner with these families on their wellness journeys,” says Ms. Liu.“Our focus on life cultivation means we are not just addressing immediate health concerns, but guiding individuals and families holistically through every stage of life, with care that evolves alongside them.” The new clinic at Punggol Coast Mall is now open. First-time patients can enjoy a special launch offer for a limited time. For more information or to register, please use our form here. Hashtag: #OrientalRemedies https://www.orientalremediesgroup.com/https://sg.linkedin.com/company/orientalremediesclinichttps://www.facebook.com/Orientalremediesgroup/https://www.instagram.com/orientalremediesclinic The issuer is solely responsible for the content of this announcement. About Oriental Remedies Clinic Oriental Remedies Clinic is a leading healthcare provider in Singapore that combines Traditional Chinese Medicine (TCM) with modern technology. The clinic has expanded from a single-physician practice to a team of bilingual practitioners, many of whom are trained in both Biomedical Science and TCM, combining

Revolutionary Cooking Sauce Defies Culinary Logic: Frozen Chicken Rivals Fresh, Budget Beef Rivals Premium Wagyu HONG KONG SAR – Media OutReach Newswire – 31 July 2025 – The revolutionary multifunctional sauce EXOTICA UMAMI (known to Chinese speakers simply as “EX M”) continues to win admirers and astound veteran chefs with its versatility, flavour,texture and remarkable time and money-saving capabilities. At another groundbreaking introduction event on July 30, presented at the New World Millennium Hong Kong Hotel, top Hong Kong chefs once again demonstrated the new seasoning and cooking sauce’s ability to generate intense, rich flavours and sometimes tenderise proteins—with results that challenged conventional culinary wisdom, showing how EXOTICA UMAMI can challenge culinary norms, improve dining experiences while potentially optimizing restaurant budgets. THE IMPOSSIBLE TASK: USING FROZEN CHICKEN TO CHALLENGE FRESH Star Chef Kenneth Loo pushed EXOTICA UMAMI to its absolute limits, taking on the extraordinary challenge of using EX M sauce in a carefully developed recipe to vacuum marinade and poach frozen chicken in direct comparison to a blind test using fresh chicken with soy sauce. In Hong Kong, using fresh chicken for soy sauce chicken is a deeply rooted practice driven by culinary tradition, as the meat needs to remain succulent while the skin takes on a shiny, flavourful finish. Fresh chicken—not frozen—is generally used because it retains natural moisture, has a tender texture, and absorbs marinade better due to its intact cell structure, resulting in juicier, more flavourful meat with a glossy, appealing skin. Frozen chicken releases excess water, has damaged cell structure, and may develop a mushy texture, reducing marinade absorption and diluting flavour while creating a drier and tougher texture when cooked. The results were nothing short of revolutionary, defying traditional belief. The consensus was that the frozen chicken marinated in “EX M” delivered a depth of flavour far more captivating than any standard soy sauce. Not only was the skin colour deeper and much more appealing, but the inherent ingredients in EXOTICA UMAMI—such as thyme and other fermented ingredients—delivered a more complex taste, dramatically enhanced juiciness and comparable texture to fresh chicken, even when the chef experimented with frozen chicken. TASTE CHALLENGE (FRESH) SOY CHICKEN VS (FROZEN) EX M POACHED CHICKEN BUDGET BEEF RIVALS PREMIUM WAGYU Moving onto the second demonstration, New World Millennium Hong Kong Hotel Executive Chef Gary Wong personally conducted an ambitious test: grilling US Ribeye steak using EXOTICA UMAMI versus M5 Wagyu Ribeye without the sauce, directly challenging the perceived superiority of premium ingredients. M5 Wagyu Ribeye, which costs approximately double that of US Ribeye, supposedly is characterised by exceptional intramuscular fat, resulting in a rich, buttery texture and a velvety, melt-in-the-mouth feel. Its fine marbling enhances tenderness and juiciness, with low-melting-point fat that should contribute to a much more luxurious bite compared to the more budget type US Ribeye Steak. TASTE CHALLENGE EXOTICA UMAMI GRILLED US RIBEYE VS GRILLED M5 WAGYU RIBEYE Once again, the results defied expectations and challenged industry assumptions. The consensus among the distinguished guests and professionals was that the US Ribeye through a few minutes of direct drizzling with “EX M” sauce in the grill made it have comparable texture in quality to the Wagyu and being equally—or more—succulent, rich and juicy than the far more expensive Wagyu. RENOWNED ITALIAN CHEF ENDORSES Also attending the demonstration was Italian chef Paolo Monti of acclaimed Wan Chai trattoria AMA. The Rome native took particular interest in EXOTICA UMAMI after learning the sauce draws inspiration from Garum, the 2,000-year-old Roman marinade. Instead of fish in Ancient Garum, creator Dan Gan developed this modern innovative alternative for salt, soy sauce and MSG using the concept of pork as the foundation. Chef Monti demonstrated a sophisticated new dish of grilled pork neck with mashed potatoes, seasoned and vacuum marinated with EXOTICA UMAMI. The refined dish captivated everyone in attendance, showcasing the sauce’s remarkable flexibility for use in authentic Italian cuisine. Chef Monti confirmed his professional endorsement: “I respect Exotica Umami for not overpowering the original taste of the main ingredients while boosting savouriness, flavours and depth—something many other seasoning products fail to achieve.” Chef Monti announced he will be serving his new pork neck dish on AMA’s menu from August 1. EXOTICA UMAMI INNOVATIVE DISHES LAUNCHED ONE AFTER ANOTHER Through this comprehensive series of chef workshops and exploration of EXOTICA UMAMI, it has become evident that the sauce delivers revolutionary, game-changing effects for enhancing dishes while achieving substantial time and cost savings. More hotels and eateries are adopting this breakthrough to their competitive advantage. In addition to Chef Monti’s announcement of his new dish, New World Millennium Hong Kong Hotel’s Sagano will serve Exotica Umami EX M Teppanyaki beef on their à la carte menu starting 1 August to give customers a different feel. Chef Cheuk will also launch EX M Poached Chicken at New World Millennium’s Tao Li as part of their reinvented Chinese “Siu Mei” specialities from August 1, joining the successful EX M Char Siu, which he created and shared with overwhelming positive feedback during the June 30 workshop. Industry professionals praised his version of the local pork char siu as comparable to Spanish pork char siu—a significant achievement in flavour and texture elevation. About EXOTICA UMAMI This all-in-one multifunctional cooking sauce and natural type flavour enhancer has emerged as a genuine game changer for the food industry. The consensus confirms that EXOTICA UMAMI makes food demonstrably more succulent and juicy while contributing its own distinctly addictive taste profile. In numerous applications, the sauce can further tenderise meat and produce. This extraordinary ability to simultaneously add flavour and improve texture saves professional kitchens significant time and money. The revolutionary alternative for salt, soy sauce and MSG was invented in Hong Kong by food visionary Dan Gan. Inspired by ancient Roman culinary heritage, it was developed and perfected at Gan’s Exotica Gelatea Restaurant through an unexpected journey. When his chef quit, Gan the proprietor was compelled to take over kitchen operations. Determined to elevate his food quality, he

SYDNEY, AUSTRALIA – Media OutReach Newswire – 31 July 2025 – Aon plc (NYSE: AON), a leading global professional services firm, has released the Australia-specific findings from its 2025 Cyber Risk Report. The report highlights the growing impact of artificial intelligence (AI)-enabled cyber attacks and the increasing exposure created by third-party technology supply chains. The report reveals that Australian organisations are facing a new frontier of cyber risk, where traditional defences are being outpaced by the speed and sophistication of AI-driven threats. “AI is no longer a future threat—it’s a present-day reality,” said Adam Peckman, head of risk consulting and cyber solutions in APAC and global head of cyber risk consulting at Aon. “We’re seeing relatively unsophisticated actors now wielding tools that rival state-sponsored capabilities. The barrier to entry has dropped dramatically, and the velocity of attacks is only increasing.” One of the most concerning developments is the emergence of AI-powered social engineering attacks. Last year saw an incident involving the theft of USD $25 million from a large UK engineering firm through a deepfake-enabled scam—an attack that has since been replicated onshore in Australia at smaller financial scale. These incidents underscore the growing accessibility and replicability of such tactics. In addition to AI threats, the report identifies technology supply chains as a critical vulnerability. A number of high-profile Australian breaches have stemmed from third-party compromises, where attackers exploit weaker security standards in vendors with privileged access to client systems. “Organisations must start treating their vendors as part of their own attack surface,” added Joerg Schmitz, Cyber Risk Quantification and Analytics Leader for APAC at Aon. “The most lucrative attacks are those that can be scaled across multiple targets through a single compromised supplier. This is a wake-up call for Australian businesses to reassess how they manage third-party risk.” Despite continued investment in cyber security, the report warns that core controls are being circumvented or rendered obsolete by evolving tactics. The use of AI to optimise every stage of the attack chain—from reconnaissance to execution—demands a fundamental rethink of defensive strategies. Aon’s 2025 Cyber Risk Report draws on CyQu data from over 3,000 clients globally and analyses more than 1,400 cyber events to identify emerging trends. The platform enables organisations to benchmark their cyber maturity, align insurance and security strategies, and make more informed, data-driven decisions. Aon’s 2025 Cyber Risk Report can be found here. Hashtag: #Aon The issuer is solely responsible for the content of this announcement. About Aon Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses. Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon’s newsroom and sign up for news alerts here.

TOKYO, JAPAN – Media OutReach Newswire – 30 July 2025 – On July 29, the 2025 “TOPAI International AI Ecosystem Frontier Private Salon” co-hosted by “TOPAI” and the “Inspiration Island Incubator,” was successfully held in Tokyo, Japan. As the first stop of “TOPAI”‘s overseas private conference, this event brought together over ten investors, scholars, technology developers, and entrepreneurs from the AI sectors of China and Japan. They engaged in deep discussions on topics such as AI technology innovation, industrial implementation, investment, entrepreneurship, and global collaboration, sharing insights that combined depth with practical value. The audience primarily consisted of AI entrepreneurs, industry observers, students from related university programs, and Japanese media. The venue was fully packed, and the atmosphere was vibrant, reflecting the high level of attention from innovative entrepreneurs in both China and Japan towards the AI field. “TOPAI” continually empowers the AI sector through in-depth content and industry reports. This private conference in Tokyo aims to serve as an important link connecting the AI ecosystems of China and Japan. The “Inspiration Island Incubator” is the first professional AI innovation incubation platform established by IMS GROUP overseas, focusing on serving content entrepreneurs and AI startups to help more AI entrepreneurial teams grow. The participating Chinese entrepreneurs in Japan have deep insights into the local market, having worked there for many years. They shared practical perspectives on core issues such as overcoming technical barriers and adapting to local market needs, based on their own experiences. Meanwhile, AI entrepreneurs from China, grounded in the rapidly iterating domestic AI technology landscape, shared explorations on key topics such as commercialization paths and globalization strategies, drawing on cutting-edge practices in areas like large model applications, content generation, and office environment innovation. In the rapidly evolving AI landscape, deep connections have become a core pathway to promoting global AI ecosystem prosperity. AI companies need to break down technical barriers and build an open, shared collaborative network, deepening cooperation in areas such as algorithm innovation, data circulation, and ethical standards. Only through collaboration can we break down silos and resolve differences, allowing AI to truly become a powerful engine driving sustainable global development. As “TOPAI” holds: true value arises from deep connections. This Tokyo private conference was not only a clash of ideas but also a weaving together of resources, trust, and vision, laying a solid foundation for AI development in China, Japan, and globally. The successful holding of the 2025 “TOPAI International AI Ecosystem Frontier Private Salon” in Tokyo is just the beginning of connections. The exchanges and discussions among industry peers here represent the true value of the private conference. As technological breakthroughs and industrial practices intersect and as trust and consensus converge, the path to a collaborative global AI ecosystem becomes increasingly clear. The “TOPAI International AI Ecosystem Frontier Private Salon” will continue to advance and expand to more cities around the world. About the Inspiration Island Incubator The Inspiration Island Incubator has opened applications for innovation projects. It provides a high-energy modern office environment for entrepreneurs at different stages of development, offering one-stop incubation services tailored for teams ranging from one-person independent offices to those with over ten members. With flexible office solutions and responsive adjustments, it truly enables a “move-in ready” experience, helping entrepreneurs launch new chapters in their careers at low costs. Hashtag: #topklout The issuer is solely responsible for the content of this announcement. About TOPAI TOPAI is a technology media registered under Beijing New Three Excellent Tech Co. LTD, primarily focusing on the latest developments in the global AI field and producing in-depth insights and authoritative reports.

“Driving the Globalization of Clinical Trials in the Guangdong-Hong Kong-Macao Greater Bay Area, Implementing the First Key Cross-Border Multi-Center Clinical Trial Project” HONG KONG SAR – Media OutReach Newswire – 30 July 2025 – The Greater Bay Area International Clinical Trial Institute of Hong Kong (“GBAICTI“), the Greater Bay Area International Clinical Trials Center of Shenzhen (“BAY TRIAL“), Immuno Cure BioTech (“Immuno Cure“) in Hong Kong are pleased to jointly announce today the signing of a tripartite Memorandum of Understanding (“MOU“) in Shenzhen on July 29, 2025. This collaboration aims to advance the globalization of clinical trials in the Guangdong-Hong Kong-Macau Greater Bay Area (“GBA“), further deepens clinical research cooperation between Hong Kong and Shenzhen, and implements the first ever cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic DNA vaccine for HIV/AIDS, developed through collaboration between Immuno Cure and the AIDS Institute at the University of Hong Kong. This marks a significant milestone in the development of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. From left to right: Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI; Dr. Xia JIN, Chief Executive Officer of Immuno Cure; Ms. TANG Hongmei, Executive Director of BAY TRIAL This collaboration is witnessed by a Hong Kong Government delegation led by the Director of Health, Dr. Ronald LAM, and a Shenzhen Government delegation led by the Deputy Director General of Public Hygiene and Health Commission of Shenzhen Municipality, Ms. ZHOU Liping, following their GBA Clinical Trial Collaboration meeting held in Shenzhen. GBAICTI and the BAY TRIAL plan to establish the GBA Clinical Trial Collaboration Platform (“Platform“) by the end of this year. The Platform is expected to offer a range of services, including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; integration of artificial intelligence technologies to assist with matching clinical trial institutions and researchers, as well as offering intelligent consultation services; establishment of a coordinated ethics review mechanism between the two regions to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; creation of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on disease areas of strength in both Shenzhen and Hong Kong. Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI, said: “The ICVAX vaccine, developed by Immuno Cure and the AIDS Institute at the University of Hong Kong, is now poised for cross-border clinical trials in the Greater Bay Area. This highlights the achievements and potential of innovation and technology in China and the Hong Kong SAR. If the clinical trial results are positive, the new vaccine would bring hope to HIV/AIDS patients worldwide, particularly in Belt and Road countries. We aim to leverage the strength of both Guangdong and Hong Kong to establish the Guangdong-Hong Kong-Macao Greater Bay Area as a global hub for clinical trials.” Dr. LI Yichong, Director of BAY TRIAL, said: “This collaboration marks the first cross border clinical trial project between the BAY TRIAL and Hong Kong, signifying a new phase in the cooperation between Shenzhen and Hong Kong in the biopharmaceutical sector of GBA. We will fully leverage the synergistic advantages of both regions to establish an international clinical trial platform with the BAY TRIAL, continuously injecting new momentum into the high-quality development of the Bay Area’s pharmaceutical and medical device industry.” Since the first discovery of AIDS in 1981, 40 million people have died from HIV infection. Currently, there are still over 39 million people living with HIV worldwide. Although antiretroviral therapy (“ART“) can effectively control HIV, it cannot cure the disease, highlighting the importance of immunotherapy. Immunotherapy aims to enhance the host’s immune response, with the expectation of controlling viral replication without ART, ultimately achieving complete viral suppression and functional cure. Immuno Cure’s ICVAX induces broad-spectrum, multifunctional virus-specific T cells to achieve the goal of controlling viral replication without ART. Immuno Cure completed the first-in-human Phase I clinical trial of the ICVAX vaccine in November 2024. The results demonstrated excellent safety and good immunogenicity. This year, two multi-center Phase II clinical trials will be conducted to evaluate the mechanism of action and efficacy, respectively, of ICVAX in humans. Both are randomized, double-blind, placebo-controlled, dose-escalation studies, with clinical trial centres in the Prince of Wales Hospital in Hong Kong and eight Grade 3A hospitals in China, including The Third People’s Hospital of Shenzhen, Beijing Ditan Hospital, Beijing Youan Hospital, Guangzhou Eighth People’s Hospital, Tianjin Second People’s Hospital, The Sixth People’s Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center. Dr. Xia JIN, Chief Executive Officer of Immuno Cure, said: “We are delighted to receive support from both GBAICTI and BAY TRIAL, integrating medical resources from both regions to advance Immuno Cure’s therapeutic vaccine for HIV, ICVAX, to multi-center Phase II clinical trials. We will continue to collaborate with the HKU AIDS Institute to drive innovation in drug development, leverage local advantages in drug research and translation, accelerate ICVAX towards commercialization, provide more effective treatment options for HIV patients, and contribute to global health.” GBAICTI, BAY TRIAL, and Immuno Cure look forward to further deepening clinical trial cooperation between Shenzhen and Hong Kong in future collaborations, jointly promoting the development and globalisation of innovative drug development, and supporting the national “Healthy China” strategic goals. Hashtag: #ImmunoCure #醫克生物 #医克生物 https://www.immunocure.hk/https://www.linkedin.com/company/immuno-cure/ The issuer is solely responsible for the content of this announcement. About GBAICTI The Greater Bay Area International Clinical Trial Institute (GBAICTI) is located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Its mission is to coordinate public and private medical resources in Hong Kong, providing a one-stop support platform for research institutions. This aims to promote process optimization, talent training, and collaboration within the Greater Bay Area, accelerating the research and development of drugs and medical devices, allowing research outcomes to benefit patients more quickly.